Ethical challenges in outbreak trial design: from Ebola to Nipah

Nipah virus causes sporadic outbreaks characterized by high mortality, with transmission concentrated within households and healthcare settings. Clinical trials of vaccines for high-mortality pathogens during outbreaks face significant methodological and ethical challenges, including due to short epidemic durations and variable community acceptance of standard individual randomized controlled trials (iRCTs). This paper examines key ethical issues in Nipah vaccine outbreak trial design. First, outbreak trials must recruit individuals at high risk of infection to reach efficacy endpoints before epidemics end, yet placebo controls may be controversial due to risks of infection among participants. Failure to accrue sufficient infections during outbreaks risks prolonged delays to vaccine licensure. Second, alternatives to classical iRCTs involve ethical and methodological trade-offs: cluster randomization may delay efficacy endpoints, especially when high transmission occurs in only a minority of clusters; trials involving delayed vaccination may involve similar risks (for control participants who are infected during the delay to vaccination) as for those in standard placebo iRCTs; and single arm trials risk failure to clarify vaccine efficacy due to their lack of controls. Third, although high pre-trial probability of experimental vaccine efficacy (>50% for recent Phase III vaccines) challenges traditional concepts of clinical equipoise, rigorous vaccine trials remain ethically acceptable. Fourth, policies for post-trial access to efficacious vaccines should be revised to provide accelerated access to control arm participants. Finally, ethical trial design depends on appropriate community engagement, which should begin early in outbreaks and ideally continue in inter-epidemic periods.